A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

By sjmartinez • August 2, 2024

Curigliano G, Jimenez MM, Shimizu T, Keam B, Meric-Bernstam F, Rutten A, Glaspy J, Schuler PJ, Parikh NS, Ising M, Hassounah N, Wu J, Leyk M, Chen X, Burks H, Chaudhury A, Otero J, Cabanas EG. A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies. ESMO Open. 2024 Jul 31;9(8):103643. doi: 10.1016/j.esmoop.2024.103643. Epub ahead of print. PMID: 39088985.

Tags: Hematology/Oncology, Keywords: LHC165; PDR001; TLR7 agonist; advanced, LHC165, PDR001, Publications, TLR7 agonist

Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative Oncology in Treatment-Related Adverse Events in the Era of Immunotherapy and Antibody-Drug Conjugates

Niknafs AM, Damron LF, Baclig NV, Iliopoulos M, Drakaki A. Threading the Needle in Bladder Cancer: A Narrative Review of the Emerging Role of Integrative[...]

Interference of Clonal Hematopoiesis in cfDNA Liquid Biopsy Testing & Identification of Actionable Alterations in Large Diverse Cohort of US Veterans

Valle LF, Scobie M, Rowe K, Pritchard CC, Montgomery B, Garraway IP, Nickols NG, Schoen MW, Kishan AU, Kelley MJ, Rettig MB, Maxwell KN. Interference[...]

Using electronic patient reported outcomes (ePROs) to improve supportive care in ambulatory oncology care: a CFIR-guided pre-implementation formative evaluation

Brauer ER, Bastani R, Cheng E, Lazaro S, Wong DJ, St John MA, Ganz PA. Using electronic patient reported outcomes (ePROs) to improve supportive care[...]